|
| Status |
Public on Feb 11, 2016 |
| Title |
The Long-HER Study |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. Some of these patients may become long-term survivors. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression to trastuzumab.
103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Sixty-five per cent of tumours were poorly differentiated ductal carcinomas and hormonal receptors were present in 47%. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median progression-free survival was 10.6 years after the diagnosis of metastatic disease. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival . Gene ontology analysis demonstrated that genes involved in HIF activation, EGF receptor signalling pathway, PI3 kinase pathway, apoptosis signalling pathway and p53 pathway significantly correlated with response. The PI3K pathway was the most strongly associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most. These findings support that trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression to trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy.
|
| |
|
| Overall design |
53 FFPE samples, which passed the RNA quality control criteria, were analyzed (45 primary tumours and 8 metastases). Among these 53 samples, 35 samples corresponded to long-term responders and 18 to the control group.
|
| |
|
| Contributor(s) |
Espinosa E, Zamora P, Fresno Vara JA, Gamez-Pozo A |
| Citation(s) |
25330188 |
| Submission date |
Feb 12, 2013 |
| Last update date |
Mar 21, 2019 |
| Contact name |
Juan Ángel Fresno Vara |
| E-mail(s) |
juanangel.fresno@idipaz.es
|
| Organization name |
Hospital La Paz
|
| Department |
INGEMM
|
| Lab |
Molecular Oncology & Pathology
|
| Street address |
Paseo de la castellana 261
|
| City |
Madrid |
| State/province |
Madrid |
| ZIP/Postal code |
28046 |
| Country |
Spain |
| |
|
| Platforms (1) |
| GPL13667 |
[HG-U219] Affymetrix Human Genome U219 Array |
|
| Samples (53)
|
|
| Relations |
| BioProject |
PRJNA189275 |
Less...
More...